Literature DB >> 31262739

Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.

Megan M Herr1, Sara J Schonfeld1, Graça M Dores1,2, Eric A Engels3, Margaret A Tucker4, Rochelle E Curtis1, Lindsay M Morton1.   

Abstract

Infectious agents have been identified in the etiology of certain non-Hodgkin lymphoma (NHL) subtypes and solid tumors. The impact of this shared etiology on risk for second cancers in NHL survivors has not been comprehensively studied. We used US population-based cancer registry data to quantify risk of solid malignancies associated with infectious etiology among 127 044 adult 1-year survivors of the 4 most common NHL subtypes diagnosed during 2000 to 2014 (mean follow-up, 4.5-5.2 years). Compared with the general population, elevated risks for liver, stomach, and anal cancers were observed among diffuse large B-cell lymphoma (DLBCL) survivors (standardized incidence ratio [SIR], 1.85; 95% confidence interval [CI], 1.46-2.31; SIR, 1.51; 95% CI, 1.16-1.94; SIR, 3.71; 95% CI, 2.52-5.27, respectively) and marginal zone lymphoma (MZL; SIR, 1.98; 95% CI, 1.34-2.83; SIR, 2.78; 95% CI, 2.02-3.74; SIR, 2.36; 95% CI, 1.02-4.64, respectively) but not follicular lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma. Anal cancer risk was particularly elevated among DLBCL survivors with HIV (SIR, 68.34; 95% CI, 37.36-114.66) vs those without (SIR, 2.09; 95% CI, 1.22-3.34). The observed patterns are consistent with shared associations between these cancers and hepatitis C virus, Helicobacter pylori, and HIV, respectively. In contrast, risks for cervical and oropharyngeal/tonsil cancers were not elevated among survivors of any NHL subtype, possibly because of the lack of NHL association with human papillomavirus or population-wide screening practices (for cervical cancer). In summary, patterns of elevated second cancer risk differed by NHL subtype. Our results suggest shared infectious etiology has implications for subsequent cancer risks among DLBCL and MZL survivors, which may help inform surveillance for these survivors.

Entities:  

Mesh:

Year:  2019        PMID: 31262739      PMCID: PMC6616262          DOI: 10.1182/bloodadvances.2019030924

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  43 in total

1.  Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Aurelien Amiot; Valerie Jooste; Charlotte Gagniere; Michaël Lévy; Christiane Copie-Bergman; Jehan Dupuis; Yann Le Baleur; Karim Belhadj; Iradj Sobhani; Corinne Haioun; Anne-Marie Bouvier; Jean-Charles Delchier
Journal:  Leuk Lymphoma       Date:  2017-01-31

2.  Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study.

Authors:  Todd M Gibson; Lindsay M Morton; Meredith S Shiels; Christina A Clarke; Eric A Engels
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

Review 3.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

4.  Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).

Authors:  Nadia Baras; Stefan Dahm; Jörg Haberland; Martin Janz; Katharina Emrich; Klaus Kraywinkel; Abdulgabar Salama
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

5.  Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

Authors:  Lindsay M Morton; Rochelle E Curtis; Martha S Linet; Elizabeth C Bluhm; Margaret A Tucker; Neil Caporaso; Lynn A G Ries; Joseph F Fraumeni
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

6.  Impact of the HIV epidemic on the incidence rates of anal cancer in the United States.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Anil K Chaturvedi; Aimee R Kreimer; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2012-10-05       Impact factor: 13.506

7.  Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study.

Authors:  L G Capelle; A C de Vries; C W N Looman; M K Casparie; H Boot; G A Meijer; E J Kuipers
Journal:  Eur J Cancer       Date:  2008-08-15       Impact factor: 9.162

8.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.

Authors:  Olivier Hermine; François Lefrère; Jean-Pierre Bronowicki; Xavier Mariette; Katayoun Jondeau; Virginie Eclache-Saudreau; Béatrice Delmas; Françoise Valensi; Patrice Cacoub; Christian Brechot; Bruno Varet; Xavier Troussard
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

9.  Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma.

Authors:  P Brennan; G Scélo; K Hemminki; L Mellemkjaer; E Tracey; A Andersen; D H Brewster; E Pukkala; M L McBride; E V Kliewer; J M Tonita; A Seow; V Pompe-Kirn; C Martos; J G Jonasson; D Colin; P Boffetta
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

10.  A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers.

Authors:  Yutaka Yasui; Yan Liu; Joseph P Neglia; Debra L Friedman; Smita Bhatia; Anna T Meadows; Lisa R Diller; Ann C Mertens; John Whitton; Leslie L Robison
Journal:  Am J Epidemiol       Date:  2003-12-01       Impact factor: 5.363

View more
  1 in total

1.  Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors.

Authors:  Lindsay M Morton
Journal:  J Clin Oncol       Date:  2020-03-31       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.